Look inside
Fourteen pages, six original charts
Every chart and the map were built for this report from the sources named in each caption. Nothing here is stock.
Page 1 of 14
Jump to a page
Japan approved the world's first iPS cell therapies in March 2026 and owns one of the most valuable oncology franchises in the industry. It is also a country where 86 medicines already approved in the West had not begun development at all.
Opened by Takeda in 2018 and run by a neutral operator since 2023. Around 190 organisations and 2,500 people on one campus in Fujisawa.
As at March 2023, Japan's health ministry identified 86 medicines already approved in Europe and the United States for which development had not even begun at home. Each square below is one of them.
medicines, March 2023. The Japan Pharmaceutical Manufacturers Association counted 82 a year later. Roughly 56 per cent came from venture-developed pipelines, 47 per cent were orphan drugs, 37 per cent were paediatric. Japan has a word for it: drug loss.
One is already generating global returns. One is a genuine world first with unproven economics. One is an attempt to rebuild a layer that atrophied.
The regulatory scaffolding was built first. The products arrived last. Select a year to see what happened.
The discovery that made everything after it possible, and the start of a fourteen-year gap between a prize and a product.
Every chart and the map were built for this report from the sources named in each caption. Nothing here is stock.
Select a beat to see what it covers.
Three questions. Most people who work in this region get at least one wrong, which is roughly the point of the report.
Three fields. Tell us where to send it and the PDF is yours.
We have also emailed a copy so you can find it later.
Download the PDF ↓
Most country reporting in our sector is written to a single verdict. A market is rising or it is stalling, promising or disappointing, and the evidence is assembled to fit. Japan defeats that method completely, which is exactly why it belongs in this series.
In the space of a few weeks this year Japan did something no other regulator on earth has done, authorising the first commercial medicines derived from induced pluripotent stem cells, and it remains a country where dozens of medicines available to patients in Europe and the United States have not begun development at all. Neither fact cancels the other. Both are produced by the same system, and a report that reconciles them into a tidy verdict has not understood the market.
So this report does not deliver one. It sets out what Japan has proved, which is considerable, and what it has not solved, which is specific and largely commercial rather than scientific.
That is the discipline the series was built on. Name the achievement, name the constraint, attribute every figure, and leave the reader to weigh them. Our job is not to tell an industry what it wants to hear about a market it is deciding whether to enter. It is to give it something accurate enough to act on.